• Kyodo

  • SHARE

Fujifilm Holdings Corp. said Thursday it expects to complete clinical tests in Japan of the antiviral drug Avigan, a potential candidate treatment drug for COVID-19, in September, already behind schedule after a delay caused by difficulty in securing enough patient data.

The last patient will participate in the clinical study Sunday and all necessary data will have been collected a month later, Fujifilm director Junji Okada said.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.

SUBSCRIBE NOW

PHOTO GALLERY (CLICK TO ENLARGE)